Cencora, Inc. · NYSE:COR
Cencora — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
15 slides from Cencora's conference presentation, Jan 13, 2025
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Bob Mauch, President and Chief Executive Officer January 13, 2025
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: Cencora is…
• Executing our pharmaceutical-centric strategy to create differentiated value for Cencora is… all our stakeholders a leading global • Driving our long-term vision of expanding pharmaceutical solutions leadership and growing higher-margin, organization with a foundation high-growth businesses in pha
Slide 4: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Advance core Enhance capabilities business and growth Why we exist We are united in our responsibility • Lead with Invest in • Expand on leadership in to create healthier futures market leaders innovation to Specialty further drive • Leverage infras
Slide 5: Cencora fiscal 2024 financial highlights
Cencora fiscal 2024 financial highlights FY24 financial highlights Revenue Adj. operating income1 Adj. free cash flow1 Adj. diluted EPS1 $294B $3.6B $3.1B $13.76 +12% y/y +11% y/y +15% y/y 1 The financial results and guidance presented are non-GAAP financial measures. For more information related to
Slide 6: Leading with leaders
Leading with leaders Partnership is at the core of our business. We work hand-in-hand with our customers to achieve their business goals and deliver healthcare excellence. Biopharma Specialty physician Health systems Pharmacy Animal health practices Companies that discover, Individuals or entities I
Slide 7: U.S. Healthcare Solutions segment
U.S. Healthcare Solutions segment Leadership in human and animal health Segment growth drivers Foundational pharmaceutical • Long-term strategic relationships with market-leading customers distribution in each channel • Specialty distribution and commercialization services contributes to our value a
Slide 8: International Healthcare Solutions segment
International Healthcare Solutions segment Differentiated global platform offers broad and deep suite Segment growth drivers of innovative services Pan-European pharmaceutical • Leading pan-European wholesaler and related solutions provider distribution • Innovative provider of upstream pharma manuf
Slide 9: Recent acquisition and investment build on our specialty legacy
Recent acquisition and investment build on our specialty legacy MSOs are the natural evolution of our position in specialty Strong foundation Investing in practice Deepens relationships furthered with management unlocks with providers and Natural evolution of our investment in the ability to better
Slide 10: Strong growth driven by execution and strategic capital deployment
Strong growth driven by execution and strategic capital deployment Adjusted diluted EPS1* Adjusted operating income1 FY20-FY24 Cumulative capital deployment 14% 5-year CAGR 12% 5-year CAGR $3.65B $13.76 $11.99 $3.29B $11.03 $3.16B $9.26 $2.65B $7.90 $7.09 $2.20B $2.05B CapEx $2.2B Confidential M&A $
Slide 11: Positioned to build on track record of driving long-term stakeholder value
Positioned to build on track record of driving long-term stakeholder value Advancing global healthcare system Strong financial profile and and capturing growth opportunities sustainable profit growth Longstanding leadership in healthcare Legacy of strong Return on Invested Capital (ROIC) Industry dr
Slide 12: Appendix
Appendix ™AN “SY Ss
Slide 13: Adjusted diluted earnings per share
Adjusted diluted earnings per share Fiscal years ended September 30, 2019, through September 30, 2024 2024 2023 2022 2021 2020 2019 GAAP diluted EPS $7.53 $8.53 $8.04 $7.39 ($16.65) $4.04 Gains from antitrust litigation settlements (0.66) (0.90) (0.01) (0.58) (0.03) (0.51) LIFO (credit) expense (0.2
Slide 14: Adjusted operating income
Adjusted operating income Fiscal years ended September 30, 2019, through September 30, 2024 (in millions) 2024 2023 2022 2021 2020 2019 GAAP operating income (loss) $2,175 $2,341 $2,366 $2,354 ($5,135) $1,112 Gains from antitrust litigation settlements (171) (239) (2) (169) (9) (146) LIFO (credit) e
Slide 15: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations and Treasury Bennett.Murphy@cencora.com 15
Cencora — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix